DR. NEDA NIKPOOR M.D.
Prescription History 1598024077
Ophthalmology in Honolulu, HI


Quality Rating: 74.86 out of 100 score

NPI Status: Active since May 03, 2012

Contact Information

615 PIIKOI ST STE 205
HONOLULU, HI
ZIP 96814
Phone: (808) 591-9911
Fax: (808) 591-9909

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. NEDA NIKPOOR M.D., an active Ophthalmology specialist practicing in Honolulu, HI. Our medical registry currently tracks 6 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 747 documented patient claims. Among these therapy options, the most frequently utilized medication is Prolensa, which accounts for 216 claims alone.

Medication Index


Besivance

Generic Formulation: Besifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 202
30-Day Fills 203.6
Days Supply 4,371
HI State Average Benchmarks
Peer Average Claims184.0
Peer Average 30-Day Fills191.9
Peer Average Days Supply4,068
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43,614.31 across this reporting matrix range.

Provider Avg Cost Per Claim

$215.91

State Avg Cost Per Claim

$207.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat bacterial eye infections. Besifloxacin belongs to a class of drugs known as quinolone antibiotics. It works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections (such as infections caused by viruses, fungi, mycobacteria). Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Lotemax Sm

Generic Formulation: Loteprednol EtabonateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 180
30-Day Fills 183.7
Days Supply 4,184
HI State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills62.1
Peer Average Days Supply1,502
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 227.3% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43,842.69 across this reporting matrix range.

Provider Avg Cost Per Claim

$243.57

State Avg Cost Per Claim

$245.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.

Therapeutic Applications

This medication is used to temporarily relieve seasonal allergy symptoms of the eyes such as swelling, redness, and itching. Loteprednol belongs to a class of drugs known as corticosteroids.

Loteprednol Etabonate

Generic Formulation: Loteprednol EtabonateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 39
30-Day Fills 39.0
Days Supply 864
HI State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills38.0
Peer Average Days Supply992
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 62.5% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,465.81 across this reporting matrix range.

Provider Avg Cost Per Claim

$165.79

State Avg Cost Per Claim

$200.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.

Therapeutic Applications

This medication is used to temporarily relieve seasonal allergy symptoms of the eyes such as swelling, redness, and itching. Loteprednol belongs to a class of drugs known as corticosteroids.

Moxifloxacin

Generic Formulation: Moxifloxacin HclSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 90
30-Day Fills 90.0
Days Supply 1,197
HI State Average Benchmarks
Peer Average Claims69.0
Peer Average 30-Day Fills71.2
Peer Average Days Supply1,079
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.4% more claims than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,139.20 across this reporting matrix range.

Provider Avg Cost Per Claim

$34.88

State Avg Cost Per Claim

$40.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.

Therapeutic Applications

This medication is a quinolone antibiotic used for eye infections.

Prednisolone Acetate

Generic Formulation: Prednisolone AcetateSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 438
HI State Average Benchmarks
Peer Average Claims108.0
Peer Average 30-Day Fills147.8
Peer Average Days Supply3,902
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 81.5% less volume than the regional standard for practitioners inside HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $598.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.92

State Avg Cost Per Claim

$55.50

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain eye conditions due to inflammation or injury. Prednisolone works by relieving symptoms such as swelling, redness, and itching. It belongs to a class of drugs known as corticosteroids.

Prolensa

Generic Formulation: Bromfenac SodiumSpecialty: Ophthalmology
Provider Metrics Summary
Total Claims 216
30-Day Fills 309.8
Days Supply 9,134
HI State Average Benchmarks
Peer Average Claims79.0
Peer Average 30-Day Fills120.9
Peer Average Days Supply3,522
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 173.4% higher than the standard regional baseline profile for HI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $71,490.13 across this reporting matrix range.

Provider Avg Cost Per Claim

$330.97

State Avg Cost Per Claim

$336.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat swelling (inflammation) and pain in the eye after a certain type of eye surgery (cataract surgery). Bromfenac belongs to a class of drugs known as nonsteroidal anti-inflammatory drugs (NSAIDs). It works by blocking the effects of certain natural substances (prostaglandins) that cause pain and inflammation.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. NEDA NIKPOOR M.D. provides transparency into local medical care patterns within Honolulu, HI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Ophthalmology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.